Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.

19 Apr 2010

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the Quantum FX, a stand-alone microCT system for preclinical imaging. Introduced at the American Association for Cancer Research Annual Meeting 2010, the Quantum FX is a low dose, microCT system that provides researchers with a 3-dimensional anatomical view of disease activity, tumor development and therapeutic response over multiple time points during the course of a study.

19 Apr 2010

Trans fats back on the agenda in UK

Dariush Mozzaffarian and Meir J Stamper, wrote an article in the British Medical Journal urging the government to ban industrial trans fatty acids or TFAs. This adds to the plea of doctors and medical charities across the country, who want to follow the example of Denmark and New York City where TFAs have been eradicated without affecting the price, taste or availability of products.

19 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

Calorie restriction may help people to lead longer and healthier lives

Organisms from yeast to rodents to humans all benefit from cutting calories. In less complex organisms, restricting calories can double or even triple lifespan. It's not yet clear just how much longer calorie restriction might help humans live, but those who practice the strict diet hope to survive past 100 years old.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range.

16 Apr 2010

LOTS results of Myozyme in older children and adults with Pompe disease published

Genzyme Corp. today announced that the results from its Late-Onset Treatment Study have been published in today's New England Journal of Medicine. The study was undertaken to evaluate the safety and efficacy of Myozyme (alglucosidase alfa) in older children and adults with Pompe disease.

16 Apr 2010

Certain genetic variations linked to tooth decay, periodontitis

Certain genetic variations may be linked to higher rates of tooth decay and aggressive periodontitis, according to two recently published papers by researchers at the University of Pittsburgh School of Dental Medicine and their collaborators.

16 Apr 2010

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.

16 Apr 2010

Takeda Pharmaceutical offers milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced it has received a $1 million milestone payment from Takeda Pharmaceutical Company Limited for achieving a pre-established preclinical milestone under the companies' 2006 collaboration agreement, which also calls for additional future milestone payments and royalties on product sales.

16 Apr 2010

EU Joint Programming initiative to tackle neurodegenerative diseases

Leading researchers from across Europe will gather today in Stockholm to develop a European-wide research strategy to tackle neurodegenerative diseases such as Alzheimer's and Parkinson's Disease.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

Artificial pancreas system succeeds in maintaining near-normal glucose levels

An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston University.

15 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

New cardiac CT technology promises low radiation exposure and improved image quality

Cardiovascular disease is the leading cause of death globally and a tremendous burden on the healthcare system. Better detection of hardening or clogging of arteries and other blood vessels before symptoms occur is needed.

15 Apr 2010

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

A brain-imaging study published today in the Archives of Neurology suggests that a major genetic risk factor for Alzheimer's disease in the Anglo population is also a risk factor for the disease in Latinos.

15 Apr 2010

Research report focuses on key influencers within employer health care market

Health Industries Research Companies' Employer & Coalition Service has released its spring 2010 market research. HIRC finds that employers are increasingly concerned about cancer medications and report sustained interest in health, wellness, and disease management initiatives.

15 Apr 2010

PROP compound linked to obesity and risk of cardiovascular disease

Whether or not you can taste a bitter compound called 6-n-propylthiouracil (or PROP) may help Professor Beverly Tepper identify your risk for becoming obese and/or developing cardiovascular disease.

15 Apr 2010

FDA approves J&JPRD's PANCREAZE NDA

Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for PANCREAZE™ (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Exocrine pancreatic insufficiency is the inability to properly digest and absorb food due to a lack of enzymes made by the pancreas that are important in the digestion of fats, proteins, and sugars.

15 Apr 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Trans fats back on the agenda in UK

VisEn Medical expands FMT imaging platform

Calorie restriction may help people to lead longer and healthier lives

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

LOTS results of Myozyme in older children and adults with Pompe disease published

Certain genetic variations linked to tooth decay, periodontitis

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Takeda Pharmaceutical offers milestone payment to XOMA

EU Joint Programming initiative to tackle neurodegenerative diseases

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Artificial pancreas system succeeds in maintaining near-normal glucose levels

Patients with RLS using rotigotine achieve sustained improvements

New cardiac CT technology promises low radiation exposure and improved image quality

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

Research report focuses on key influencers within employer health care market

PROP compound linked to obesity and risk of cardiovascular disease

FDA approves J&JPRD's PANCREAZE NDA

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in